Skip to main content
SpringerLink
Log in

mTOR Pathway and mTOR Inhibitors in Cancer Therapy

  • Book
  • © 2010

Overview

Editors:
  1. Vitaly A. Polunovsky

    1. Dept. Family Medicine, University of Minnesota, Minneapolis, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Peter J. Houghton

    1. Director, Center for Childhood Cancer, Nationwide Children’s Hospital, The Research Institute, Columbus, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (13 chapters)

  1. Front Matter

    Pages i-xii
    Download chapter PDF

  2. mTORC1: A Signaling Integration Node Involved in Cell Growth

    • Neil Kubica, John Blenis
    Pages 1-36

  3. The Regulation of the IGF-1/mTOR Pathway by the p53 Tumor Suppressor Gene Functions

    • Zhaohui Feng, Arnold J. Levine
    Pages 37-48

  4. mTOR Signaling in Angiogenesis

    • Henry Mead, Mirjana Zeremski, Markus Guba
    Pages 49-74

  5. mTORC1 Signaling and Hypoxia

    • James Brugarolas
    Pages 75-97

  6. mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside

    • David Akhavan, Paul S. Mischel
    Pages 99-111

  7. mTOR and Cancer Therapy: General Principles

    • Peter J. Houghton
    Pages 113-131

  8. mTOR and Cancer Therapy: Clinical Development and Novel Prospects

    • Sandrine Faivre, Thomas Decaens, Eric Raymond
    Pages 133-148

  9. Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer

    • Madlaina Breuleux, Heidi A. Lane
    Pages 149-178

  10. Downstream Targets of mTORC1

    • Bruno D. Fonseca, Christopher G. Proud
    Pages 179-200

  11. Downstream of mTOR: Translational Control of Cancer

    • Ryan J. O. Dowling, Nahum Sonenberg
    Pages 201-216

  12. Genome-Wide Analysis of Translational Control

    • Ola Larsson, Peter B. Bitterman
    Pages 217-236

  13. Translational Control of Cancer: Implications for Targeted Therapy

    • Peter B. Bitterman, Vitaly A. Polunovsky
    Pages 237-255

  14. Downstream from mTOR: Therapeutic Approaches to Targeting the eIF4F Translation Initiation Complex

    • Jerry Pelletier, Jeremy R. Graff
    Pages 257-285

  15. Back Matter

    Pages 287-301
    Download chapter PDF
Back to top

Keywords

About this book

The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment – targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.

Editors and Affiliations

  • Dept. Family Medicine, University of Minnesota, Minneapolis, USA

    Vitaly A. Polunovsky

  • Director, Center for Childhood Cancer, Nationwide Children’s Hospital, The Research Institute, Columbus, USA

    Peter J. Houghton

Bibliographic Information

  • Book Title: mTOR Pathway and mTOR Inhibitors in Cancer Therapy

  • Editors: Vitaly A. Polunovsky, Peter J. Houghton

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-1-60327-271-1

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer Science+Business Media, LLC 2010

  • Hardcover ISBN: 978-1-60327-270-4Published: 02 August 2010

  • Softcover ISBN: 978-1-61779-694-4Published: 13 October 2012

  • eBook ISBN: 978-1-60327-271-1Published: 23 July 2010

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: XII, 304

  • Topics: Cancer Research, Cell Biology, Pharmacology/Toxicology

Publish with us

Policies and ethics

Back to top

Search

Navigation